155 related articles for article (PubMed ID: 38363526)
41. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
[TBL] [Abstract][Full Text] [Related]
42. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
Garrison LP; Veenstra DL
Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
[TBL] [Abstract][Full Text] [Related]
43. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
Le QA; Bae YH; Kang JH
Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
[TBL] [Abstract][Full Text] [Related]
44. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
45. Designing an Optimum Fiscal Policy for Tobacco to Maximise the Tax Revenue, Social Savings and the Net Monetary Benefits in Sri Lanka.
Perera SK; Vaikuntam BP; John D; Senanayake B
Int J Health Policy Manag; 2020 Jun; 9(6):250-256. PubMed ID: 32613793
[TBL] [Abstract][Full Text] [Related]
46. Social Security, retirement incentives, and retirement behavior: an international perspective.
Gruber J; Wise D
EBRI Issue Brief; 1999 May; (209):1-22. PubMed ID: 10539446
[TBL] [Abstract][Full Text] [Related]
47. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
[TBL] [Abstract][Full Text] [Related]
48. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
49. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study).
Antolín Novoa S; Escrivá-de-Romaní S; Tolosa Ortega P; Oliva Fernández L; López López R; López González A; de la Morena Barrio P; Echavarria Díaz-Guardamino I; Alés Martinez JE; Garate Z; González-Cortijo L
Cancer Treat Res Commun; 2023; 37():100772. PubMed ID: 37995519
[TBL] [Abstract][Full Text] [Related]
50. Motor vehicle safety, health care, and taxes. National Highway Traffic Safety Administration, U.S. Department of Transportation.
Prehosp Disaster Med; 1994; 9(1):11-23. PubMed ID: 10155483
[TBL] [Abstract][Full Text] [Related]
51. Public economic gains from tax-financed investments in childhood immunization in the United States.
Connolly MP; Kotsopoulos N; Roberts C; Kotlikoff L; Bloom DE; Hu T; Nyaku M
PLOS Glob Public Health; 2023; 3(10):e0002461. PubMed ID: 37851624
[TBL] [Abstract][Full Text] [Related]
52. The macroeconomic impacts of diet-related fiscal policy for NCD prevention: A systematic review.
Mounsey S; Veerman L; Jan S; Thow AM
Econ Hum Biol; 2020 May; 37():100854. PubMed ID: 32062400
[TBL] [Abstract][Full Text] [Related]
53. The health and economic burden of smoking in 12 Latin American countries and the potential effect of increasing tobacco taxes: an economic modelling study.
Pichon-Riviere A; Alcaraz A; Palacios A; Rodríguez B; Reynales-Shigematsu LM; Pinto M; Castillo-Riquelme M; Peña Torres E; Osorio DI; Huayanay L; Loza Munarriz C; de Miera-Juárez BS; Gallegos-Rivero V; De La Puente C; Del Pilar Navia-Bueno M; Caporale J; Roberti J; Virgilio SA; Augustovski F; Bardach A
Lancet Glob Health; 2020 Oct; 8(10):e1282-e1294. PubMed ID: 32971051
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
55. Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?
Wu J; Kong R; Tian S; Li H; Wu K; Kong L
Chin J Cancer Res; 2019 Dec; 31(6):878-891. PubMed ID: 31949390
[TBL] [Abstract][Full Text] [Related]
56. Tax reform, population ageing and the changing labour supply behaviour of married women.
Apps P
J Popul Econ; 1991; 4(3):201-16. PubMed ID: 12316986
[TBL] [Abstract][Full Text] [Related]
57. The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs.
Kotsopoulos N; Connolly MP; Willis M; Nilsson A; Ericsson Å; Baker-Knight J
Diabetes Obes Metab; 2022 Jun; 24(6):1038-1046. PubMed ID: 35137507
[TBL] [Abstract][Full Text] [Related]
58. The fiscal impact of informal caregiving to home care recipients in Canada: how the intensity of care influences costs and benefits to government.
Jacobs JC; Lilly MB; Ng C; Coyte PC
Soc Sci Med; 2013 Mar; 81():102-9. PubMed ID: 23347496
[TBL] [Abstract][Full Text] [Related]
59. Estimating the Product Lifecycle Value of Trastuzumab Based on Registry Data in Sweden.
Justo N; Wilking N; Jönsson L
Clin Drug Investig; 2023 Jul; 43(7):529-540. PubMed ID: 37422544
[TBL] [Abstract][Full Text] [Related]
60. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G; Huang CS; Mano MS; Loibl S; Mamounas EP; Untch M; Wolmark N; Rastogi P; Schneeweiss A; Redondo A; Fischer HH; Jacot W; Conlin AK; Arce-Salinas C; Wapnir IL; Jackisch C; DiGiovanna MP; Fasching PA; Crown JP; Wülfing P; Shao Z; Rota Caremoli E; Wu H; Lam LH; Tesarowski D; Smitt M; Douthwaite H; Singel SM; Geyer CE;
N Engl J Med; 2019 Feb; 380(7):617-628. PubMed ID: 30516102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
